Study of Bevacizumab Eye Injections With or Without Oral Curcumin for Diabetic Macular Edema

What this Trial Is About

Researchers are evaluating the effectiveness of adding oral curcumin treatment to intravitreal injections of bevacizumab in patients with diabetic macular edema. This randomized, single-blind clinical trial aims to compare two groups one receiving bevacizumab plus curcumin, and the other receiving bevacizumab plus a placebo. The primary goals are to assess the central thickness and volume of the macula, while also measuring the best visual acuity as a secondary outcome. The study involves two intervention groups. Both groups receive intravitreal injections of bevacizumab at a standard dose of 1.25 mg0.05 ml, administered three times at monthly intervals. In the curcumin group, participants also take oral curcumin tablets twice daily at 40 mg each for three months, starting alongside the bevacizumab treatment. The control group takes matching placebo tablets on the same schedule. Participants will be monitored over a three-month period with assessments of macular thickness, macular volume, and visual acuity. These evaluations help determine the effects of the treatments on diabetic macular edema. Safety and treatment response are tracked throughout the study, which is conducted under medical supervision to ensure participant well-being and adherence to the treatment protocol.

Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin